ArticleProceedings of the National Academy of Sciences of the United States of America2019
Bladder drug mirabegron exacerbates atherosclerosis through activation of brown fat-mediated lipolysis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 79 citations in OpenAlex.
- The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans.The Journal of clinical investigation · 2020Trial
- Stigmasterol-Based EGCG Liposomes Reduce Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)lysine (CEL) in a Model System and Cookies.Foods (Basel, Switzerland) · 2026Article
- Reexamining Fat: Exploring Diversity, Plasticity, Development, Functional Implication, and Therapeutic Options.International journal of molecular sciences · 2026Review
- Brown and beige adipose tissue-derived metabokine and lipokine inter-organ signalling in health and disease.Experimental physiology · 2025Review
- Impact of β3-adrenergic receptor agonist on tumor progression and metastasis in renal cell carcinoma models.Cancer cell international · 2025Article
- Salt-inducible Kinase Regulation of Adipose Tissue Metabolism.Endocrinology · 2025Review
- Brown adipose tissue detection using positron emission tomography could help reduce urolithiasis risk.Urolithiasis · 2025Article
- Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition.Frontiers in pharmacology · 2025Article
- Article
- An Updated Structure of Oxybutynin Hydrochloride.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Effective Prevention and Treatment of Acute Leukemias in Mice by Activation of Thermogenic Adipose Tissues.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Lycopene andPharmaceuticals (Basel, Switzerland) · 2024Article
- CMKLR1 senses chemerin/resolvin E1 to control adipose thermogenesis and modulate metabolic homeostasis.Fundamental research · 2024Article
- Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004-2023).Frontiers in pharmacology · 2024Article
- Atherosclerosis: an overview of mouse models and a detailed methodology to quantify lesions in the aortic root.Vascular biology (Bristol, England) · 2024Review
- Cross-talks between perivascular adipose tissue and neighbors: multifaceted nature of nereids.Frontiers in pharmacology · 2024Review
- Cancer-triggered systemic disease and therapeutic targets.Holistic integrative oncology · 2024Article
- Distinct Conformations of Mirabegron Determined by MicroED.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Therapeutic Potential for Beta-3 Adrenoreceptor Agonists in Peripheral Arterial Disease and Diabetic Foot Ulcers.Biomedicines · 2023Review
- Mirabegron displays anticancer effects by globally browning adipose tissues.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabegron (Myrbetriq) is a β3-adrenoreceptor agonist approved for treating overactive bladder syndrome in human patients. This drug can activate brown adipose tissue (BAT) in adult humans and rodents through the β3-adrenoreceptor-mediated sympathetic activation. However, the effect of the mirabegron, approved by the US Food and Drug Administration, on atherosclerosis-related cardiovascular disease is unknown. Here, we show that the clinical dose of mirabegron-induced BAT activation and browning of white adipose tissue (WAT) exacerbate atherosclerotic plaque development. In apolipoprotein E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.